In an innovative leap bridging oncology and neurology, recent multicenter research has identified the Advanced Lung Cancer Inflammation Index (ALI) as a significant prognostic marker for patients experiencing acute ischemic stroke (AIS) and undergoing intravenous thrombolysis (IVT). Originally utilized within oncological contexts to gauge systemic inflammation and nutritional status, ALI’s application in cerebrovascular events could revolutionize stroke prognosis and patient management strategies.
The study, conducted across three prominent stroke centers in China, scrutinized a cohort of 784 patients diagnosed with AIS who received IVT therapy within 4.5 hours from symptom onset. This therapeutic window is critical as thrombolytic treatment efficacy hinges heavily on rapid administration. The researchers embarked on a detailed follow-up extending to three months post-treatment, applying the modified Rankin Scale (mRS) as the metric for functional outcome evaluation. Notably, scores of 2–6 on the mRS were categorized as non-excellent outcomes, denoting any degree of disability or mortality.
Central to the study was the analysis of ALI levels measured early in the stroke treatment timeline. ALI, a composite index derived from body mass index (BMI), serum albumin concentrations, and the neutrophil-to-lymphocyte ratio (NLR), offers an integrative view of systemic inflammatory status and body reserves. The investigators found a compelling inverse correlation between ALI and the probability of adverse outcome: patients presenting with lower ALI values were significantly more likely to endure functional impairments at three months post-stroke.
Statistical rigor was maintained by controlling for an array of confounding variables often implicated in stroke prognosis, including age, baseline stroke severity, comorbidities, and treatment delays. After adjustment, individuals falling into the lowest ALI quartile exhibited nearly double the risk of poor functional recovery compared to those in the highest quartile, with an odds ratio of 0.487 (95% CI: 0.310–0.767). This relationship underscores ALI’s potential as a robust and independent predictor of recovery trajectory.
Beyond conventional linear assessments, the research employed restricted cubic spline analysis to delve deeper into the nature of this association. Results revealed a non-linear, J-shaped curve signifying that risk of unfavorable outcomes escalates sharply below the 25th percentile of ALI values but stabilizes above this threshold. This nuanced threshold effect highlights that maintaining ALI above a critical level could be pivotal in reducing stroke-related disability.
Within the clinical context, the constituents of ALI – BMI, albumin, and NLR – are readily obtainable through routine labs and physical assessments, making ALI an accessible and cost-effective tool. Serum albumin reflects nutritional status and systemic inflammation, while NLR is a widely recognized marker of immune system activation and inflammatory burden. By synthesizing these parameters, ALI encapsulates a comprehensive picture of patient resilience against ischemic injury.
The implications of these findings are profound. Early risk stratification based on ALI could empower clinicians to identify high-risk individuals who may benefit from intensified monitoring, adjunctive therapies, or targeted rehabilitation. Moreover, integrating ALI into clinical protocols might refine patient selection for IVT, which carries inherent bleeding risks, ensuring that only those with favorable inflammatory profiles are subjected to treatment.
This research also invites exploration into the pathophysiological mechanisms linking systemic inflammation and AIS outcomes. Elevated inflammation, as indicated by low ALI, likely exacerbates ischemic brain injury through endothelial dysfunction, disruption of the blood-brain barrier, and perpetuation of neuroinflammation. Conversely, better-nourished and less inflamed patients may possess intrinsic protective mechanisms facilitating neural recovery.
The study is published in the inaugural issue of Translational Neurology and Neurosurgery, under the title “Relationship between Advanced Lung Cancer Inflammation Index and 3-month Outcome in Acute Ischemic Stroke Patients Treated with Intravenous Thrombolysis.” This peer-reviewed article marks a significant interdisciplinary advancement, suggesting that an oncologic inflammation index can transcend its original scope to provide meaningful prognostic insights in stroke care.
As the global burden of stroke continues to escalate, particularly in aging populations, innovations such as this are invaluable. ALI could soon become an essential biomarker within stroke units worldwide, supplementing neuroimaging and traditional clinical scales with biochemical prognostication. This multidimensional approach aligns with precision medicine aspirations, optimizing therapeutic decisions to individual biological profiles.
Looking ahead, further research is warranted to validate ALI’s utility across diverse populations and clinical settings, including patients undergoing endovascular therapy or those with hemorrhagic stroke. Additionally, prospective interventional trials could investigate whether modifying components of ALI, such as improving nutritional status or dampening systemic inflammation, translates to improved neurological outcomes.
The convergence of systemic inflammation markers with stroke prognosis embodies the evolving understanding of stroke as a multisystem disease influenced by complex interactions between immunity, metabolism, and vascular pathology. ALI’s emergence from lung cancer prognostication into stroke medicine exemplifies the cross-pollination of disciplines driving modern biomedical innovation.
In summary, the Advanced Lung Cancer Inflammation Index stands out as a promising, practical, and predictive biomarker for assessing 3-month functional outcomes in AIS patients receiving intravenous thrombolysis. Its incorporation into clinical practice could herald a new era of tailored stroke care, reducing disability and enhancing recovery for millions worldwide.
Subject of Research: Not applicable
Article Title: Relationship between Advanced Lung Cancer Inflammation Index and 3-month Outcome in Acute Ischemic Stroke Patients Treated with Intravenous Thrombolysis
News Publication Date: 31-Mar-2026
Web References:
https://dx.doi.org/10.2738/TNN.2026.0002
https://journal.hep.com.cn/tnn/EN/10.2738/TNN.2026.0002
Image Credits: HIGHER EDUCATION PRESS
Keywords: Acute Ischemic Stroke, Intravenous Thrombolysis, Advanced Lung Cancer Inflammation Index, Systemic Inflammation, Prognostic Biomarker, Modified Rankin Scale, Neutrophil-to-Lymphocyte Ratio, Serum Albumin, Body Mass Index, Stroke Recovery, Risk Stratification, Translational Neurology
Tags: Advanced Lung Cancer Inflammation Index in stroke prognosisbody mass index as a stroke recovery predictorinflammationinflammation markers in acute ischemic strokeintravenous thrombolysis timing and outcomesmodified Rankin Scale for stroke functional assessmentmultidisciplinary approaches in stroke and cancer researchneutrophil-to-lymphocyte ratio in stroke patientsnutritional status and cerebrovascular diseaseprognostic biomarkers in acute ischemic stroke treatmentserum albumin levels and ischemic stroke outcomessystemic inflammation impact on stroke recovery
